Active substance
Alfentanil
- SFDA 2
- US FDA 2
- NHS prices 3
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| RAPIFEN 500MCG-ML AMP | 500 µ/ml | Solution for injection/infusion · Intravenous use | 5 Ampoule | SAR 82.95 | NCE · Prescription | Piramal Critical Care B.V | Valid |
| RAPIFEN 500MCG-ML AMP | 500 µ/ml | Solution for injection/infusion · Intravenous use | 5 Ampoule | SAR 19.45 | NCE · Prescription | Piramal Critical Care B.V | Valid |
Indications — CHI Daman Drug Formulary
ANESTHESIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ALFENTA | EQ 0.5MG BASE/ML | injectable · injection | RISING | Prescription | 29 Dec 1986 |
| ALFENTANIL | EQ 0.5MG BASE/ML | injectable · injection | HOSPIRA | Discontinued | 28 Oct 1999 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Alfentanil 1mg/2ml solution for injection ampoules | £9.00 | 10 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Alfentanil 5mg/10ml solution for injection ampoules | £31.00 | 10 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Alfentanil 5mg/1ml solution for injection ampoules | £25.00 | 10 ampoule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 22 Dec 2025 ALFENTA — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.